Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content